Zentiva will release its 3Q consolidated IFRS figures today, October 31 at 12:00pm CET. Apart from seasonal effects meaning higher sales and lower margins in 3Q, Zentiva’s results should be positively impacted by the continued focus on higher margin branded products and improved material sourcing, including higher consumption of Active Pharmaceutical Ingredients (APIs) it produces itself. Operating costs should be seasonally below 2Q figures. Nevertheless, we expect a yoy increase in sales&marketing cost categories due to foreign expansion and the promotion of branded products. Lower debt and corporate tax should positively impact the bottom line. At the conference call we will be looking for more details regarding the recent acquisition of Sicomed. The conference call will be held today at 4:30pm CET (3:30pm UK). Dial-in no.: +44-207 162 0125.
IFRS Consolidated (CZK m) 9M2005E 9M2004 % change Consensus
Sales 8,305 7,844 5.9% 8 307
Gross Profit 5,255 4,842 8.5% -
EBIT 2,021 2,000 1.0% 2 059
Pre-tax income 2,030 1,886 7.7% -
Net income 1,460 1,194 22.3% 1,464
EPS (CZK, annualized) 51.0 47.1 22.3% 51.2